Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Change in Account Payables (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Change in Account Payables for 8 consecutive years, with -$1.0 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 1558.33% to -$1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$737000.0 through Dec 2025, up 64.84% year-over-year, with the annual reading at -$737000.0 for FY2025, 64.84% up from the prior year.
  • Change in Account Payables for Q4 2025 was -$1.0 million at Precision Biosciences, down from $220000.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $2.0 million in Q4 2023, with the low at -$2.1 million in Q1 2024.
  • Average Change in Account Payables over 5 years is -$15250.0, with a median of $60000.0 recorded in 2021.
  • The sharpest move saw Change in Account Payables soared 708.33% in 2022, then tumbled 1558.33% in 2025.
  • Over 5 years, Change in Account Payables stood at $627000.0 in 2021, then tumbled by 45.77% to $340000.0 in 2022, then skyrocketed by 489.12% to $2.0 million in 2023, then plummeted by 96.41% to $72000.0 in 2024, then crashed by 1558.33% to -$1.0 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$1.0 million, $220000.0, and $199000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.